AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.

11/12/2026, 3:40 AM • GlobeNewswire

DaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnerships

DaltonTx announced the appointment of Melissa Landon, Ph.D., as Chief Commercial Officer to lead commercial strategy and expand adoption of its Dalton platform across pharma, biotech, and CRO partners. Landon brings 20+ years of AI/ML experience in drug discovery, most recently from Merck KGaA/MilliporeSigma, and previously served as Chief Strategy Officer at Cyclica.

11/12/2026, 3:30 AM • GlobeNewswire

1 Big Winner and 1 Loser From the Upcoming Anthropic IPO

Anthropic's upcoming IPO will have divergent impacts on companies in the AI and biotech sectors. Broadcom stands to benefit significantly from a $161.2 billion, five-year non-cancellable agreement to provide AI chip capacity to Anthropic. Conversely, Recursion Pharmaceuticals faces headwinds as Anthropic's Claude AI model becomes a standard tool for drug discovery among major pharmaceutical companies, eroding Recursion's competitive advantage despite the biotech having no approved drugs since its 2013 founding.

10/31/2026, 6:45 PM • The Motley Fool

AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider

The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.

09/07/2026, 8:30 AM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

The Market Just Told You Which Layer Of AI Biology It Is Paying For

Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.

09/03/2026, 2:10 PM • GlobeNewswire

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

08/25/2026, 12:46 PM • GlobeNewswire

AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine

Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.

08/06/2026, 10:52 AM • GlobeNewswire

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion's Compensation Committee approved the grant of 3,234,866 inducement restricted stock units to 24 new employees on July 27, 2026, as part of its 2024 Inducement Equity Incentive Plan. The awards will vest quarterly over four years, subject to continued employment.

07/31/2026, 4:30 PM • GlobeNewswire

3 Stocks With the Most Upside by the End of 2026

The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceuticals, an AI-driven drug discovery platform trading over 100% below analyst consensus with multiple developmental milestones approaching.

07/30/2026, 4:30 PM • The Motley Fool

2 Beaten-Down Stocks That Still Aren't Worth Buying

The article argues that Recursion Pharmaceuticals and Sarepta Therapeutics, despite significant stock declines, remain unattractive investments. Recursion has no approved products and faces competition in AI-driven drug discovery. Sarepta struggles with safety concerns around its lead therapy Elevidys and faces an uncertain path to regaining market confidence despite some clinical progress.

07/11/2026, 4:30 PM • The Motley Fool

Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and Development

The generative AI in drug discovery market is experiencing significant expansion, growing from $0.25 billion in 2025 to $0.33 billion in 2026, with projections to reach $0.86 billion by 2030 at a 27% CAGR. Key drivers include rising drug development costs, computational chemistry advancements, increased biological datasets, and strategic collaborations between AI firms and pharmaceutical companies. Major players are leveraging AI-driven tools for molecule generation, deep learning in drug design, and accelerated early-stage development.

07/10/2026, 10:55 AM • GlobeNewswire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest actively purchased shares in Tesla, SoFi Technologies, and Recursion Pharmaceuticals on Thursday. Tesla delivered 480,126 vehicles in Q2, exceeding analyst expectations by 74,000 units, though the stock fell 7.35% on the day. SoFi, which Ark bought every trading day this week, continues to demonstrate strong growth metrics with a Rule of 40 score of 72. Recursion Pharmaceuticals, an AI-driven drug discovery company, represents a longer-term speculative bet for Wood's portfolio.

07/05/2026, 6:03 AM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Nvidia's venture capital arm has invested $13 million in Generate Biomedicines, a biotech company developing an AI platform for virtual drug testing. The platform addresses major pharmaceutical industry challenges by reducing development time and costs, with AI-discovered drugs showing twice the success rate in phase 1 trials. This investment signals Nvidia's confidence in the company's potential to transform the $1.8 trillion pharmaceutical market.

06/27/2026, 7:23 AM • The Motley Fool